- Home
- TXG
as 04-24-2025 3:44pm EST
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 1.3B | IPO Year: | 2019 |
| Target Price: | $19.79 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.78 - $29.37 | Next Earning Date: | 05-08-2025 |
| Revenue: | $610,785,000 | Revenue Growth: | -1.28% |
| Revenue Growth (this year): | 0.76% | Revenue Growth (next year): | 9.28% |
Stock Insider Trading Activity of 10x Genomics Inc. (TXG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saxonov Serge | TXG | Chief Executive Officer | Feb 28 '25 | Sell | $10.63 | 7,942 | $84,393.28 | 871,540 | |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 24 '25 | Sell | $11.07 | 5,092 | $56,346.04 | 871,540 | |
| Hindson Benjamin J. | TXG | See Remarks | Feb 24 '25 | Sell | $11.07 | 4,573 | $50,602.99 | 335,324 | |
| MATEO ALAN | TXG | Director | Feb 21 '25 | Buy | $11.14 | 40,000 | $445,572.00 | 61,691 |
Latest 10x Genomics Inc. News
TXG Breaking Stock News: Dive into TXG Ticker-Specific Updates for Smart Investing
PR Newswire
10 days ago
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
MT Newswires
10 days ago
BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained
StockStory
15 days ago
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
StockStory
15 days ago
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
Simply Wall St.
a month ago
We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth
FastCompany
a month ago
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
StockStory
a month ago
2 Reasons to Sell TXG and 1 Stock to Buy Instead
PR Newswire
2 months ago
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
Compare TXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.